Sanskruti Pharma Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sanskruti Pharma Pharmaceutical Export Portfolio Dataset — 2 Products, $84.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sanskruti Pharma — Pharmaceutical Exporter Profile (2026) | 2 Products, $84.9K Trade | TransData Nexus

Sanskruti Pharma

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $84.9K Total Trade · DGFT Verified

Sanskruti Pharma is an Indian pharmaceutical exporter with a total trade value of $84.9K across 2 products in 1 therapeutic categories. Based on 71 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Rituximab ($71.6K), Regorafenib ($13.3K), .

Sanskruti Pharma — Export Portfolio & Destination Treemap

Sanskruti Pharma pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sanskruti Pharma? — Company Overview & Market Position

Sanskruti Pharma, established in 2007, is a privately held pharmaceutical company headquartered in Surat, Gujarat, India. The company operates as a trader, wholesaler, distributor, and exporter of pharmaceutical products, including tablets, capsules, syrups, and injections. Sanskruti Pharma is registered under the Goods and Services Tax (GST) with the number 24CVJPS6320K2Z8 and holds an Import Export Code (IEC) of CVJPS6320K. The firm's annual turnover ranges between ₹1.5 to ₹5 crore, and it employs between 11 to 25 individuals.

The company's legal status is that of a proprietorship, with Mr. Champakbhai Rudabhai Saliya serving as the proprietor. Sanskruti Pharma's registered office is located at Basement Part No-3, Plot No-100, 100/A, 101, 102, 103, Vasudev Nagar Society, Ved Road, Dabholi, Surat-395004, Gujarat, India.

What Does Sanskruti Pharma Export? — Product Portfolio Analysis

Top Products by Export Value

1Rituximab$71.6K 2Regorafenib

Product Portfolio — Top 2 by Export Value

Sanskruti Pharma exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rituximab	Advanced Oncology	$71.6K	62	0.4%	12
2	Regorafenib	Advanced Oncology	$13.3K	9	1.3%	2

Sanskruti Pharma exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $84.9K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sanskruti Pharma — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sanskruti Pharma operates manufacturing facilities in Surat, Gujarat, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding plant capacities and certifications are not publicly disclosed, the company emphasizes adherence to stringent quality control and testing procedures to ensure product safety and efficacy.

3Key Leadership

Mr. Champakbhai Rudabhai Saliya serves as the proprietor of Sanskruti Pharma. The company's leadership team includes Mr. Chirag Saliya, who holds the position of Chief Executive Officer (CEO). Specific details regarding other key executives, such as the Chief Financial Officer (CFO), are not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sanskruti Pharma Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sanskruti Pharma's export activities are primarily focused on the African and Latin American markets, including countries such as Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Cuba, the Dominican Republic, and Haiti. The company has not publicly disclosed specific regulatory filings, approvals, or market access statuses in the United States, European Union, United Kingdom, Australia, or Japan.

2Emerging Markets

Sanskruti Pharma has a significant presence in emerging markets, particularly in Africa and Latin America. The company's focus on these regions aligns with the World Health Organization's (WHO) prequalification program, which aims to ensure the quality, safety, and efficacy of medical products. By adhering to WHO prequalification standards, Sanskruti Pharma enhances its credibility and facilitates access to these markets.

3Geographic Strategy

Sanskruti Pharma's export strategy demonstrates a concentrated approach, focusing heavily on the African and Latin American markets. This geographic concentration may expose the company to risks associated with regional economic fluctuations, political instability, and regulatory changes. Diversifying its export destinations could mitigate these risks and provide a more balanced growth trajectory.

Sanskruti Pharma — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sanskruti Pharma has not publicly disclosed any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection histories. The company's export activities are primarily directed towards markets in Africa and Latin America, where FDA approvals may not be a prerequisite. However, obtaining FDA approvals could enhance the company's credibility and open avenues in additional regulated markets.

2WHO & EU GMP

Sanskruti Pharma has not publicly disclosed certifications such as WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. These certifications are crucial for accessing regulated markets and ensuring product quality. Pursuing such certifications could bolster the company's reputation and facilitate entry into more stringent markets.

3CDSCO & Indian Regulatory

Sanskruti Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, which are essential for domestic and international operations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

Sanskruti Pharma — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sanskruti Pharma operates in a competitive landscape with numerous pharmaceutical exporters targeting similar markets in Africa and Latin America. While specific competitors are not publicly identified, the company's focus on oncology medicines, anti-cancer injections, and other specialized pharmaceutical products positions it in a niche segment. Differentiating through product quality, regulatory compliance, and customer service is crucial for maintaining a competitive edge.

2Key Differentiators

Sanskruti Pharma's key differentiators include its specialization in oncology medicines and anti-cancer injections, catering to critical healthcare needs in emerging markets. The company's commitment to quality, safety, and compliance with international standards enhances its reputation among healthcare providers and patients. Additionally, its focus on emerging markets allows for tailored strategies that address specific regional healthcare challenges.

3Strategic Position

Sanskruti Pharma's current strategic direction emphasizes the export of specialized pharmaceutical formulations, particularly in the oncology segment, to emerging markets. The company's future outlook would benefit from diversifying its product portfolio, obtaining international certifications, and exploring new market opportunities to enhance growth and sustainability.

Buyer Due Diligence Brief — Evaluating Sanskruti Pharma as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sanskruti Pharma demonstrates a consistent track record in exporting pharmaceutical products, with a total export value of $85,000 USD across 71 shipments. The company's portfolio is concentrated, with its top two products—Rituximab and Regorafenib—accounting for 100% of its export value. This concentration indicates a focused approach but also suggests potential risks associated with market fluctuations affecting these specific products.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the FDA directly.

WHO-GMP Certification: Ensure that the manufacturing facilities adhere to the World Health Organization's Good Manufacturing Practice standards. This can be verified by reviewing the WHO's list of prequalified manufacturers.

Frequently Asked Questions — Sanskruti Pharma

How many pharmaceutical products does Sanskruti Pharma export from India?

Sanskruti Pharma exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Rituximab ($71.6K), Regorafenib ($13.3K). Total export value is $84.9K.

What is Sanskruti Pharma's total pharmaceutical export value?

Sanskruti Pharma's total pharmaceutical export value is $84.9K, based on 71 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sanskruti Pharma cover?

Sanskruti Pharma exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Sanskruti Pharma Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.